Literature DB >> 7901231

Reduced interleukin-2 (IL-2) production in common variable immunodeficiency is due to a primary abnormality of CD4+ T cell differentiation.

E M Eisenstein1, J S Jaffe, W Strober.   

Abstract

Common variable immunodeficiency (CVI) is a condition characterized by hypogammaglobulinemia and impaired antibody responses, resulting in recurrent bacterial infections in untreated patients. In addition, affected individuals exhibit an increased incidence of autoimmunity, malignancy, and certain viral infections, suggesting the presence of an underlying generalized immune dysregulation. We have previously described a subgroup of CVI patients in whom T cells within PBMC populations exhibit a selective defect in lymphokine production. IL-2, IL-4, and IL-5 mRNA production was impaired in these patients, while proliferation, IL-2R expression, and c-myc mRNA production were normal. In the present series of experiments, using highly purified CD4+ T cells prepared by negative selection, we show that this lymphokine production defect is a primary abnormality of CVI CD4+ T cells: whereas CD4+ T cells from CVI patients proliferate normally in response to stimulation by PHA, staphylococcal enterotoxin B (SEB), or anti-CD2 antibodies, these stimuli induce significantly less IL-2 production than observed with CD4+ T cells from normal individuals. Furthermore, we show that this IL-2 production defect is not due to an accessory cell abnormality, since it was seen in the presence of normal (allogeneic) accessory cells, and patient accessory cells supported normal amounts of IL-2 production by PHA-stimulated CD4+ T cells obtained from normal individuals. Of interest, we also found that while IL-2 production by CD4+ T cells from CVI patients induced by stimulation with immobilized anti-CD3 antibody was reduced compared to CD4+ T cells from normal control individuals, this reduction was not statistically significant. Furthermore, stimulation of both CVI patient and normal CD4+ T cells with either ionomycin+phorbol myristate acetate or a combination of immobilized anti-CD3 antibody plus anti-CD28 antibody resulted in a 50-fold increase in IL-2 production compared to stimulation with immobilized anti-CD3 antibody alone, and, under these conditions, CVI and normal CD4+ T cells produced equivalent amounts of IL-2. Finally, minor defects in interferon-gamma production by CD4+ T cells from CVI donors were observed, but these were less severe than the IL-2 production defects and were not statistically significant. We conclude that a primary abnormality of lymphokine production exists in the CD4+ T cells of a subset of patients with CVI.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7901231     DOI: 10.1007/bf00919383

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  26 in total

1.  Activation of T cells by a tyrosine kinase activation domain in the cytoplasmic tail of CD3 epsilon.

Authors:  F Letourneur; R D Klausner
Journal:  Science       Date:  1992-01-03       Impact factor: 47.728

2.  Profound block in thymocyte development in mice lacking p56lck.

Authors:  T J Molina; K Kishihara; D P Siderovski; W van Ewijk; A Narendran; E Timms; A Wakeham; C J Paige; K U Hartmann; A Veillette
Journal:  Nature       Date:  1992-05-14       Impact factor: 49.962

3.  Clinical and immunologic analyses of 103 patients with common variable immunodeficiency.

Authors:  C Cunningham-Rundles
Journal:  J Clin Immunol       Date:  1989-01       Impact factor: 8.317

Review 4.  Basis and implications of selectively diminished cytokine production in neonatal susceptibility to infection.

Authors:  C B Wilson; D B Lewis
Journal:  Rev Infect Dis       Date:  1990 May-Jun

5.  Abnormalities of lymphokine gene expression in patients with common variable immunodeficiency.

Authors:  M C Sneller; W Strober
Journal:  J Immunol       Date:  1990-05-15       Impact factor: 5.422

Review 6.  The staphylococcal enterotoxins and their relatives.

Authors:  P Marrack; J Kappler
Journal:  Science       Date:  1990-05-11       Impact factor: 47.728

7.  Accessory cell independent proliferation of human T4 cells stimulated by immobilized monoclonal antibodies to CD3.

Authors:  T D Geppert; P E Lipsky
Journal:  J Immunol       Date:  1987-03-15       Impact factor: 5.422

8.  Functional abnormalities of CD8+ T cells define a unique subset of patients with common variable immunodeficiency.

Authors:  J S Jaffe; W Strober; M C Sneller
Journal:  Blood       Date:  1993-07-01       Impact factor: 22.113

Review 9.  Common variable immunodeficiency: the disorder and treatment.

Authors:  M W Yocum; J M Kelso
Journal:  Mayo Clin Proc       Date:  1991-01       Impact factor: 7.616

10.  Structural mutations of the T cell receptor zeta chain and its role in T cell activation.

Authors:  S J Frank; B B Niklinska; D G Orloff; M Merćep; J D Ashwell; R D Klausner
Journal:  Science       Date:  1990-07-13       Impact factor: 47.728

View more
  15 in total

1.  IgH sequences in common variable immune deficiency reveal altered B cell development and selection.

Authors:  Krishna M Roskin; Noa Simchoni; Yi Liu; Ji-Yeun Lee; Katie Seo; Ramona A Hoh; Tho Pham; Joon H Park; David Furman; Cornelia L Dekker; Mark M Davis; Judith A James; Kari C Nadeau; Charlotte Cunningham-Rundles; Scott D Boyd
Journal:  Sci Transl Med       Date:  2015-08-26       Impact factor: 17.956

2.  Opioid treatment of experimental pain activates nuclear factor-κB.

Authors:  Peggy Compton; Charles Griffis; Elizabeth Crabb Breen; Matthew Torrington; Ryan Sadakane; Eshetu Tefera; Michael R Irwin
Journal:  J Opioid Manag       Date:  2015 Mar-Apr

3.  Thymic and bone marrow output in patients with common variable immunodeficiency.

Authors:  Federico Serana; Paolo Airò; Marco Chiarini; Cinzia Zanotti; Mirko Scarsi; Micol Frassi; Vassilios Lougaris; Alessandro Plebani; Luigi Caimi; Luisa Imberti
Journal:  J Clin Immunol       Date:  2011-04-14       Impact factor: 8.317

4.  Deficiency of somatic hypermutation of immunoglobulin G transcripts is a better predictor of severe respiratory tract infections than lack of memory B cells in common variable immunodeficiency.

Authors:  Lone Schejbel; Hanne Marquart; Vagn Andersen; Henrik Permin; Pernille Andersen; Arne Svejgaard; Torben Barington
Journal:  J Clin Immunol       Date:  2005-07       Impact factor: 8.317

5.  CD95 expression and function on lymphocyte subpopulations in common variable immunodeficiency (CVID); related to increased apoptosis.

Authors:  J Iglesias; N Matamoros; S Raga; J M Ferrer; J Mila
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

6.  Common variable immunodeficiency (CVID) and MxA-protein expression in blood leucocytes.

Authors:  J A Rump; D Jakschiess; U Walker; M Schlesier; P von Wussow; H H Peter
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

7.  A double-blind, placebo-controlled, crossover therapy study with natural human IL-2 (nhuIL-2) in combination with regular intravenous gammaglobulin (IVIG) infusions in 10 patients with common variable immunodeficiency (CVID).

Authors:  J A Rump; A Jahreis; M Schlesier; S Stecher; H H Peter
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

8.  Defective integration of activating signals derived from the T cell receptor (TCR) and costimulatory molecules in both CD4+ and CD8+ T lymphocytes of common variable immunodeficiency (CVID) patients.

Authors:  V Thon; H M Wolf; M Sasgary; J Litzman; A Samstag; I Hauber; J Lokaj; M M Eibl
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

Review 9.  Autoimmunity in common variable immunodeficiency.

Authors:  Susana Lopes-da-Silva; Luiz Vicente Rizzo
Journal:  J Clin Immunol       Date:  2008-04-29       Impact factor: 8.317

Review 10.  Autoimmunity in common variable immunodeficiency.

Authors:  Shradha Agarwal; Charlotte Cunningham-Rundles
Journal:  Curr Allergy Asthma Rep       Date:  2009-09       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.